Publication | Closed Access

Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report

UrologyCancer ImmunosurveillanceGenitourinary CancerMedicineHereditary LeiomyomatosisPathologyComplete ResponseImmune Checkpoint InhibitorOncologyCase Report